Simcyp Limited releases new version of the
Simcyp Population-based ADME Simulator
Sheffield, UK, 3rd April 2008 – Simcyp Limited, the
leader in predictive pharmacokinetics, has released Version 8.0 of the ‘Simcyp
Population-based ADME Simulator’, an advanced platform for the modelling and
simulation of drug absorption, distribution, metabolism and elimination (ADME)
in virtual populations. The new features incorporated into Version 8.0 were
determined in consultation with the Simcyp Consortium, which currently
includes nine out of the top ten pharmaceutical companies worldwide.
The Simcyp Simulator allows preclinical data to be used to maximum advantage
in drug development; informing the design of human studies and allowing ‘what
if’ questions to be explored in the safety of a computer.
Executive Director of Simcyp, Dr Steve Toon said: “It is estimated that in the
near future up to 15% of drug development budgets will be spent on modelling
and simulation, and the benefits to the industry are rapidly becoming
apparent. For example, complex multiple drug-drug interactions involving
various enzyme inhibition or induction mechanisms can now be simulated using
the Simcyp platform as a prelude to undertaking a clinical study. This not
only helps optimise the study design but minimises the risk to the clinical
study subjects.”
Simcyp simulations incorporate known population variability; this produces
relevant ‘real world’ predictions which are more informative than simulations
performed in a single ‘average’ reference man. In addition to modelling the
fate of drugs in Caucasian and Japanese populations, the Simcyp Simulator can
also predict drug-fate in patients with liver cirrhosis, renal impairment or
obesity. On top of this, a ‘healthy volunteer’ library within the platform
allows drug companies to carry out virtual Phase I studies, which can help
improve the design of real studies in humans.
Commenting on the new release, Professor Amin Rostami-Hodjegan, Director of
Research and Development at Simcyp said: “The recent enhancements to the
Simcyp Simulator will prove particularly useful to scientists working in
pharmaceutics, as the Simcyp absorption model can now accommodate a variety of
different drug formulations. Many factors which affect the subsequent
bioavailability of a drug, including food intake, variability in pH and
concentration-dependent effects of efflux transporters in the gut, can now
also be simulated using Simcyp.”
– Ends –
About Simcyp
Simcyp is a research-based company providing a modelling and simulation
platform for predicting the fate of drugs in virtual populations. From this,
individual patients likely to be at extreme risk from adverse drug reaction
can be identified, and unnecessary exposure to human volunteers and animals
can be minimised. The clinical limitations of candidate compounds, including
potential drug-drug interactions, can be assessed and managed prior to human
studies, allowing better focus of drug development resources.
Scientific development at Simcyp is guided by a Consortium of leading
pharmaceutical companies, ensuring that Simcyp’s products and services
continue to meet, and exceed, industry needs. Simcyp maintains strong academic
links and conducts internationally recognised research and development. The
Company also offers consultancy services, and runs education programmes around
the world.
For further information, please visit our website at
www.simcyp.com .
Media enquiries:
College Hill Life Sciences:
Tristan Jervis, Tony Stephenson, Claire Mosley
Phone: +44 20 7457 2020
Email: simcyp@collegehill.com
